Clinical trials: Metastatic Neoplasm
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma
This phase I trial identifies the best dose of ipilimumab that can be administered through the DoseConnect™ device followed by nivolumab in treating patients with stage III melanoma that cannot be removed by surgery…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Unresectable Melanoma
- Trial name
- NCT04967196
- Testing
- Ipilimumab, Nivolumab, Lymph Node Assessment
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Mayo Clinic
Metastatic Melanoma, Skin Cancer
Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma
Background: Researchers have developed an experimental cancer treatment called cell therapy. White blood cells called lymphocytes are taken from a tumor, grown in large numbers in the lab, and then given back to the patient.
- Trial name
- NCT01369888
- Testing
- Cyclophosphamide, Fludarabine, Tumor Infiltrating Lymphocytes
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Breast Cancer
Determine Feasibility of Quantifying Apoptosis and Bcl-2 Expression in CTCs in Women With Metastatic Breast Cancer
We are trying to develop better ways to detect when cancer therapies are working.
- Trial name
- NCT00156273
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- University of Michigan Rogel Cancer Center
Cervical Cancer, Recurrent Cervical Cancer
Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer
Drug: Cabozantinib Drug: Pembrolizumab
- Conditions
- Cervical Cancer, Recurrent Cervical Cancer, Metastatic Cervical Cancer, Persistent Cervical Cancer
- Trial name
- NCT04230954
- Testing
- Cabozantinib 40 MG oral once a day, Pembrolizumab 200 mg IV every 3 weeks
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of South Alabama
HER2-Negative Breast Cancer
Study on the Treatment of HER2-negative Breast Cancer Brain Metastases With Radiotherapy Combined With Anlotinib
Angiogenesis inhibition represents a significant therapeutic target in breast cancer; however, despite its theoretical feasibility, progress in advanced breast cancer has been slow.
- Trial name
- NCT07396454
- Testing
- Radiotherapy Combined with Anlotinib and a Microtubule Inhibitor
- Where
- China
- Volunteers
- 39 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Castration-resistant Prostate Cancer
Response Evaluation of Cancer Therapeutics in Metastatic Castration-Resistant Prostate Cancer to the Bone
This study is aimed to compare whole body MRI (WB-MRI) with Bone Scintigraphy (BS) and Computerized Tomography (CT) scans in patients receiving treatment for metastatic castration-resistant prostate cancer to the bone.
- Trial name
- RESPECT (NCT06321679)
- Testing
- Imaging evaluation
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- European Institute of Oncology
Breast Cancer, Metastatic Breast Cancer
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
The purpose of this study is to determine whether lucitanib is safe and effective in the treatment of patients with FGF aberrant metastatic breast cancer, as well as in the treatment of patients with biomarker negative (FGF…
- Conditions
- Breast Cancer, Metastatic Breast Cancer, MBC, HER2 Positive
- Trial name
- NCT02202746
- Testing
- Lucitanib
- Where
- 33 sites in United States
- Volunteers
- 178 people
- Sponsor
- Clovis Oncology, Inc.
Chemotherapy-induced Peripheral Neuropathy, Colorectal Cancer Stage II
Effect of Hemp-CBD on Patients With CIPN
The purpose of this study is to assess the effect of a hemp-based cannabidiol (CBD) product, Ananda Hemp Spectrum Gelcaps, on the severity and duration of chemotherapy-induced neuropathy (CIPN) among non-metastatic breast…
- Conditions
- Chemotherapy-induced Peripheral Neuropathy, Colorectal Cancer Stage II, Colorectal Cancer Stage III, Breast Cancer
- Trial name
- Coala-T-CBD (NCT04398446)
- Testing
- Hemp-based CBD
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Main Line Health
Brain Micrometastases
RCT of the 4mm vs. the 8mm Collimator for GKR of Brain Micrometastases
Gamma Knife Radiosurgery (GKR) is a well-established treatment modality for brain metastasis (Chiou 2013; Salvetti, Nagaraja et al. 2013).
- Trial name
- NCT02220127
- Testing
- GKR with a single shot of the 8 mm collimator, GKR with a single shot of the 4 mm collimator
- Where
- 3 sites in United Kingdom
- Volunteers
- 298 people
- Sponsor
- University College, London
Solid Tumor
CD73/AXL Targeted HypoSti.CAR-T Cells in CD73/AXL Positive Advanced/Metastatic Solid Tumors
In this single-center, single-arm,prospective, open-label, phase 1/2 study, the safety and efficacy of novel autologous hypoxia-activated CAR-T cell therapy targeting CD73 and AXL ( CD73/AXL.HypoSti.CAR-T) will be evaluated in…
- Trial name
- NCT06939270
- Testing
- CD73/AXL.HypoSti.CAR-T cells, Albumin-Bound Paclitaxel, Cyclophosphamide
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
Metastatic Non-Small Cell Lung Cancer
Real-World Assessment of Clinical Outcomes in Metastatic NSCLC Patients With MET Exon 14 Skipping Mutation and Brain Metastases Treated With Capmatinib
This was a retrospective, noninterventional cohort study of patients with a confirmed diagnosis of metastatic NSCLC with MET Exon 14 skipping mutation and brain metastases (BM) who received treatment with capmatinib in real-world…
- Trial name
- NCT05675683
- Testing
- Capmatinib
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma
LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer
This phase Ib/II trial investigates the side effects and best dose of LY3214996 when given together with cetuximab alone or in combination with abemaciclib and to see how well they work in treating patients with colorectal cancer…
- Conditions
- Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma, Recurrent Colorectal Carcinoma
- Trial name
- NCT04616183
- Testing
- Abemaciclib, Cetuximab, ERK1/2 Inhibitor LY3214996
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Colorectal Cancer
Fruquintinib Combined With mFOLFOX6/FOLFIRI in First-line Treatment for Metastatic Colorectal Cancer
The purpose of this study is to evaluate the efficacy and safety of Fruquintinib Combined With mFOLFOX6/FOLFIRI as the first-line treatment of Metastatic Colorectal Cancer
- Trial name
- NCT05004441
- Testing
- Fruquintinib Combined With mFOLFOX6/FOLFIRI
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Zhou Fuxiang
NSCLC
ctDNA Dynamic Monitoring and Its Role of Prognosis in Stage II to IIIA NSCLC by NGS
The second generation of high-throughput gene sequencing (NGS) is an important means of detecting the tumor DNA and circulating tumor DNA (ctDNA), which can detect trace ctDNA from smaller plasma samples.
- Trial name
- NCT03465241
- Testing
- the ctDNA dynamic monitoring
- Where
- China
- Volunteers
- 119 people
- Sponsor
- Sun Yat-sen University
Estrogen Receptor Negative, Estrogen Receptor Positive
Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer
The purpose of the study is to evaluate the impact on progression-free survival (PFS) with the combination carboplatin - pembrolizumab in patients with CTC (circulating tumor cells) positive, HER2 negative metastatic breast…
- Conditions
- Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Negative
- Trial name
- NCT03213041
- Testing
- Carboplatin, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Northwestern University
Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
An open-label, controlled, multi-site, interventional, 2-arm, Phase II/III trial of BNT113 in combination with pembrolizumab vs pembrolizumab monotherapy as first line treatment in patients with unresectable recurrent or…
- Conditions
- Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer
- Trial name
- AHEAD-MERIT (NCT04534205)
- Testing
- BNT113, Pembrolizumab
- Where
- 138 sites in United States, Argentina and 19 more
- Volunteers
- 358 people
- Sponsor
- BioNTech SE
Breast Cancer With Brain Metastases
Pyrotinib Combined With Capecitabine and Bevacizumab for Patients With HER2 Positive Breast Cancer and Brain Metastases
This study intends to conduct a small, prospective, single-center clinical study to explore and evaluate the efficacy and safety of pyrrotinib combined with capecitabine and bevacizumab in HER2-positive advanced breast cancer…
- Trial name
- NCT06152822
- Testing
- pyrotinib+capecitabine+bevacizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tongji Hospital
HER2-positive Breast Cancer
A Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients of China With HER2-positive Unresectable or Metastatic Breast Cancer
This is a multicenter, non-interventional, retrospective, real-world study that enrolled patients diagnosed with HER2-positive unresectable or metastatic breast cancer.
- Trial name
- NCT05769751
- Testing
- Electronic medical record and hospital information system or other available resources
- Where
- 5 sites in China
- Volunteers
- 865 people
- Sponsor
- Daiichi Sankyo
Metastatic Melanoma
A Study Investigating SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma Patients
Thi pahse I, dose-escalation trial will determine the MTD, safety and the additional benefit achieved from adding SGI-110 to ipilimumab therapy in metastatic melanoma patients.
- Trial name
- NIBIT-M4 (NCT02608437)
- Testing
- SGI-110, Ipilimumab
- Where
- Italy
- Volunteers
- 19 people
- Sponsor
- Italian Network for Tumor Biotherapy Foundation
Melanoma, Renal Cell Carcinoma
A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors
In this four-part study, NKTR-214 was administered in combination with nivolumab and with/without other anticancer therapies. Part 1 considered escalating doublet (NKTR 214 + nivolumab) doses to determine the RP2D.
- Conditions
- Melanoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Urothelial Carcinoma
- Trial name
- PIVOT-02 (NCT02983045)
- Testing
- Dose Escalation Doublet: Combination of NKTR-214 + nivolumab, Dose Expansion Doublet: Combination of NKTR-214 + nivolumab, Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab
- Where
- 58 sites in United States, Belgium and 6 more
- Volunteers
- 557 people
- Sponsor
- Nektar Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.